Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Phathom Pharmaceuticals Inc (PHAT)

Phathom Pharmaceuticals Inc (PHAT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 893,581
  • Shares Outstanding, K 78,799
  • Annual Sales, $ 175,110 K
  • Annual Income, $ -221,250 K
  • EBIT $ -160 M
  • EBITDA $ -156 M
  • 60-Month Beta 0.61
  • Price/Sales 5.01
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 120.73% (-25.48%)
  • Historical Volatility 66.82%
  • IV Percentile 46%
  • IV Rank 15.28%
  • IV High 461.32% on 05/07/25
  • IV Low 59.29% on 08/20/25
  • Expected Move (DTE 11) 2.21 (19.73%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 14
  • Volume Avg (30-Day) 553
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 22,801
  • Open Int (30-Day) 18,465
  • Expected Range 8.99 to 13.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.27
  • Number of Estimates 1
  • High Estimate $-0.27
  • Low Estimate $-0.27
  • Prior Year $-1.15
  • Growth Rate Est. (year over year) +76.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.00 +12.00%
on 03/24/26
11.90 -5.88%
on 03/20/26
+0.53 (+4.97%)
since 03/06/26
3-Month
10.00 +12.00%
on 03/24/26
18.09 -38.09%
on 01/07/26
-5.17 (-31.58%)
since 01/06/26
52-Week
2.21 +406.79%
on 05/08/25
18.31 -38.83%
on 12/23/25
+6.32 (+129.51%)
since 04/04/25

Most Recent Stories

More News
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal...

PHAT : 11.16 (-1.59%)
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Over 1.1 million total VOQUEZNA ® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating...

PHAT : 11.16 (-1.59%)
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 11.16 (-1.59%)
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 11.16 (-1.59%)
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 11.16 (-1.59%)
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 11.16 (-1.59%)
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 11.16 (-1.59%)
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 11.16 (-1.59%)
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

First patient dosed, with topline results expected in 2027 pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04,...

PHAT : 11.16 (-1.59%)
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 11.16 (-1.59%)

Business Summary

Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel treatments for gastrointestinal diseases. The company's product pipeline consists of vonoprazan, which are in clinical stage. Phathom Pharmaceuticals Inc. is based in Buffalo...

See More

Key Turning Points

3rd Resistance Point 12.11
2nd Resistance Point 11.74
1st Resistance Point 11.54
Last Price 11.16
1st Support Level 10.97
2nd Support Level 10.60
3rd Support Level 10.40

See More

52-Week High 18.31
Fibonacci 61.8% 12.16
Last Price 11.16
Fibonacci 50% 10.26
Fibonacci 38.2% 8.36
52-Week Low 2.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.